SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Xiaorong Dong

Status and phase: Unknown; Phase 2

Conditions: Sintilimab; Brain Metastases; NSCLC Stage IV; SRS

Treatments: Combination Product: SRS sequential sintilimab

Study type: Interventional

Funder types: Other

Identifiers

NCT04180501

sintilimab

Details and patient eligibility

About

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-small cell lung cancer patients with less than brain metastases
• Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment
• Patients who have not received intracranial local treatment before

Exclusion criteria

• Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds
• Patients with hemorrhage in intracranial metastasis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

SRS sequential sintilimab

Experimental group

Treatment:

Combination Product: SRS sequential sintilimab